Adial Pharmaceuticals, Inc.

NasdaqCM:ADIL Stock Report

Market Cap: US$6.4m

Adial Pharmaceuticals Valuation

Is ADIL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ADIL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ADIL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ADIL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ADIL?

Key metric: As ADIL is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ADIL. This is calculated by dividing ADIL's market cap by their current book value.
What is ADIL's PB Ratio?
PB Ratio1.1x
BookUS$5.88m
Market CapUS$6.41m

Price to Book Ratio vs Peers

How does ADIL's PB Ratio compare to its peers?

The above table shows the PB ratio for ADIL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.2x
CNSP CNS Pharmaceuticals
1.7x54.7%US$5.8m
EVOK Evoke Pharma
1.5x124.7%US$6.5m
POLX.F Polydex Pharmaceuticals
1.4xn/aUS$6.8m
MSTH Mystic Holdings
0.4xn/aUS$6.5m
ADIL Adial Pharmaceuticals
1.1x6.2%US$6.4m

Price-To-Book vs Peers: ADIL is good value based on its Price-To-Book Ratio (1.1x) compared to the peer average (1.2x).

Price to Book Ratio vs Industry

How does ADIL's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

24 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.09xn/aUS$8.82m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.72m
UPC Universe Pharmaceuticals
0.1xn/aUS$2.85m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.43m
ADIL 1.1xIndustry Avg. 1.7xNo. of Companies31PB01.22.43.64.86+
24 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ADIL is good value based on its Price-To-Book Ratio (1.1x) compared to the US Pharmaceuticals industry average (1.7x).

Price to Book Ratio vs Fair Ratio

What is ADIL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ADIL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ADIL's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ADIL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.99
US$7.50
+656.8%
6.7%US$8.00US$7.00n/a2
Nov ’25US$1.01
US$7.50
+642.6%
6.7%US$8.00US$7.00n/a2
Oct ’25US$0.97
US$7.50
+670.5%
6.7%US$8.00US$7.00n/a2
Sep ’25US$0.98
US$7.50
+664.5%
6.7%US$8.00US$7.00n/a2
Aug ’25US$1.02
US$7.50
+635.3%
6.7%US$8.00US$7.00n/a2
Jul ’25US$1.09
US$7.50
+588.1%
6.7%US$8.00US$7.00n/a2
Jun ’25US$1.45
US$7.50
+417.2%
6.7%US$8.00US$7.00n/a2
May ’25US$1.76
US$7.50
+326.1%
6.7%US$8.00US$7.00n/a2
Apr ’25US$1.23
US$14.50
+1,078.9%
44.8%US$21.00US$8.00n/a2
Feb ’25US$1.15
US$17.00
+1,378.3%
52.9%US$26.00US$8.00n/a2
Jan ’25US$1.86
US$17.00
+814.0%
52.9%US$26.00US$8.00n/a2
Dec ’24US$1.91
US$17.00
+790.0%
52.9%US$26.00US$8.00n/a2
Nov ’24US$2.18
US$17.00
+679.8%
52.9%US$26.00US$8.00US$1.012
Oct ’24US$2.78
US$20.50
+637.4%
61.0%US$33.00US$8.00US$0.972
Sep ’24US$4.21
US$20.50
+386.9%
61.0%US$33.00US$8.00US$0.982
Apr ’24US$8.75
US$187.50
+2,042.9%
20.0%US$225.00US$150.00US$1.232
Mar ’24US$11.25
US$187.50
+1,566.7%
20.0%US$225.00US$150.00US$3.262
Feb ’24US$11.50
US$212.50
+1,747.8%
5.9%US$225.00US$200.00US$1.152
Jan ’24US$5.38
US$212.50
+3,853.5%
5.9%US$225.00US$200.00US$1.862
Dec ’23US$6.50
US$212.50
+3,169.2%
5.9%US$225.00US$200.00US$1.912
Nov ’23US$7.25
US$212.50
+2,830.0%
5.9%US$225.00US$200.00US$2.182

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

7D

2.4%

1Y

20.0%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$59.39

7D

7.8%

1Y

20.6%

IQVIA Holdings

US$36.5b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

7D

3.6%

1Y

-5.8%